Median Technologies (XPAR:ALMDT) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALMDT Median Technologies XPAR:ALMDT
49 GF Score
Price €4.11
GF Value €1.73
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Median Technologies Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

XPAR:ALMDT
49GF Score
Median Technologies XPAR:ALMDT
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Median Technologies (XPAR:ALMDT) Overvalued in 2026?

Based on GuruFocus' analysis, Median Technologies stock appears to be overvalued. The current stock price of €4.11 is trading 137.6% above its estimated GF Value™ of €1.73. GuruFocus considers Median Technologies to be Significantly Overvalued.

Key valuation signals for XPAR:ALMDT:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €1.73 vs. price of €4.11 (137.6% above fair value)
  • GF Score™: 49/100 with 8 warning signs

No single metric tells the full story. See the XPAR:ALMDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Median Technologies Business Description

Other Exchanges 4ZG:Germany
Address 1800 Route Des Cretes, Les Deux Arcs, Building B, Valbonne, FRA, 06560
Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The company focuses on the oncology clinical trials market and the cancer patient care market. The company has two platforms, iSee for imaging services in clinical trials and eyonis for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer. Its revenue is generated from contracts for providing imaging services for oncology clinical trials using dedicated software. Geographically, the company generates revenue from EMEA, the USA/Canada, and China.
49GF Score

Get the complete analysis for XPAR:ALMDT

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.11
Price
€1.73
GF Value